GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remedent Inc (OTCPK:REMI) » Definitions » PE Ratio (TTM)
中文

Remedent (Remedent) PE Ratio (TTM) : At Loss (As of Apr. 24, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Remedent PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-24), Remedent's share price is $0.055. Remedent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.02. Therefore, Remedent's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Remedent's PE Ratio (TTM) or its related term are showing as below:

REMI' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



REMI's PE Ratio (TTM) is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 27.17 vs REMI: At Loss

Remedent's Earnings per Share (Diluted) for the three months ended in Dec. 2020 was $0.01. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.02.

As of today (2024-04-24), Remedent's share price is $0.055. Remedent's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.02. Therefore, Remedent's PE Ratio without NRI for today is At Loss.

Remedent's EPS without NRI for the three months ended in Dec. 2020 was $0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.02.

Remedent's EPS (Basic) for the three months ended in Dec. 2020 was $0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.02.


Remedent PE Ratio (TTM) Historical Data

The historical data trend for Remedent's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remedent PE Ratio (TTM) Chart

Remedent Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.00 6.75 At Loss 1.82 At Loss

Remedent Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 At Loss At Loss At Loss At Loss

Competitive Comparison of Remedent's PE Ratio (TTM)

For the Medical Instruments & Supplies subindustry, Remedent's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remedent's PE Ratio (TTM) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Remedent's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Remedent's PE Ratio (TTM) falls into.



Remedent PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Remedent's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.055/-0.015
=At Loss

Remedent's Share Price of today is $0.055.
Remedent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Remedent  (OTCPK:REMI) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Remedent PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Remedent's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Remedent (Remedent) Business Description

Traded in Other Exchanges
N/A
Address
Zuiderlaan 1-3, Box 8, Ghent, BEL, 9000
Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States. The product line of the company includes SmileWise, the SmileMe mirror, and the Condor intra-oral 3D scanner.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Gruber & Mcbaine Capital Management Llc 10 percent owner 234 VAN NESS, STE 5, SAN FRANCISCO CA 94133
Stephen Farley Ross director, officer: CFO; Secretary XAVIER DE COCKLAAN 42 DEURLE C9 9831
Fred Kolsteeg director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Acker Philippe Van director C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831
Robin List other: Former Officer and Director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Roger Leddington officer: Sr VP & Head of US Marketing C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 DEURLE C9 9831
Guy Devreese director, officer: Chairman of the Board XAVIER DE COCKLAAN 42 DEURLE C9 9831
Judd Darrin Hoffman officer: VP Worldwide Sales/Operations 702A JUANITA AVENUE REDONDO BEACH CA 90277
Nv Lausha 10 percent owner C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831

Remedent (Remedent) Headlines

From GuruFocus

Making Money from Smiles

By Frank Lind Frank Lind 05-26-2011